Under construction – not a live service
Sign in
Taking people in IndiaPhase 3

Eloralintide for Obstructive Sleep Apnea in Adults With Obesity or Overweight

Tests eloralintide in adults with obstructive sleep apnea and excess weight.

Key facts

Who runs it
Eli Lilly and Company
Where
Bengaluru, Bhubaneswar, Guntur, Nagpur, New Delhi, Pune, Raipur, Rishikesh, Thane, and Vadodara, IndiaSee the 12 sitesAlso in 10 other countries, 103 sites
Registry title
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Status
Recruiting
Phase
Phase 3
People taking part
800 people, planned
Started
10 Feb 2026
Expected to end
Apr 2028
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Eloralintide
  • Placebo
Record updated
4 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with moderate-to-severe obstructive sleep apnea who also have obesity or overweight. It tests once-weekly eloralintide against placebo.

Age
18 years or older
Sex
All sexes can join
Disease stage
Moderate-to-severe obstructive sleep apnea (AHI ≥ 15 on a sleep study at screening) with a BMI ≥27 kg/m2
Earlier treatment
At least one self-reported unsuccessful dietary effort to lose weight. One part of the study is for people who cannot or will not use PAP therapy. The other part is for people who have used PAP for at least 3 months and plan to continue.

Main reasons for not taking part

  • Any type of diabetes
  • Past or planned surgery or device treatment for obesity (some exceptions apply)
  • Past or planned surgery for sleep apnea or major ear, nose or throat surgery that may still affect breathing
  • Heart attack, stroke, heart artery procedure, unstable angina or hospital stay for heart failure within 90 days before screening
  • Weight-loss medicines or remedies within 90 days before screening

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Confirmed history of moderate-to-severe OSA
  • Have an AHI ≥ 15 on polysomnography (PSG) as part of the study at screening
  • Have a BMI ≥27 kg/m2 at screening
  • Have a stable body weight (<5% body weight change) for 90 days prior to screening
  • Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight; For YSA1 Participants:
  • Are unable or unwilling to use PAP therapy; For YSA2 Participants:
  • Have been on PAP therapy for at least three consecutive months prior to screening and plan to continue PAP therapy during the study

Who cannot take part

  • Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening)
  • Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
  • Any previous or planned surgery for sleep apnea or major ear, nose or throat surgery that still may affect breathing at time of screening
  • Have had within 90 days prior to screening:; acute myocardial infarction; cerebrovascular accident (stroke); coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure
  • Have taken medications or alternative remedies intended for weight loss within 90 days of screening
  • Have type 1 diabetes, type 2 diabetes, or any other type of diabetes
  • Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure

Where in India

Also in 10 other countries, 103 sites

  • SDS Tuberculosis Research Center & Rajiv Gandhi Institute of Chest DiseasesBengaluru, IndiaContact: Akshata S (principal investigator)Not yet recruiting
  • St. Johns Medical College HospitalBengaluru, IndiaContact: UMA MAHESWARI KRISHNASWAMY (principal investigator)Not yet recruiting
  • Utkal Institute of Medical Sciences and HospitalBhubaneswar, IndiaContact: Satyajeet Sahoo (principal investigator)Taking people
  • Endolife Speciality HospitalsGuntur, IndiaContact: GADDIPATI BABU (principal investigator)Taking people
  • KRIMS HospitalNagpur, IndiaContact: Ashok Arbat (principal investigator)Taking people
  • All India Institute of Medical SciencesNew Delhi, IndiaContact: Saurabh Mittal (principal investigator)Taking people
  • Sir Ganga Ram HospitalNew Delhi, IndiaContact: Sanjay Manchanda (principal investigator)Taking people
  • Deenanath Mangeshkar Hospital & Research CentrePune, IndiaContact: Balasaheb Pawar (principal investigator)Taking people
  • All India Institute of Medical SciencesRaipur, IndiaContact: Dibakar Sahu (principal investigator)Taking people
  • All India Institute of Medical Sciences, RishikeshRishikesh, IndiaContact: Lokesh Saini (principal investigator)Taking people
  • Bhakti Vedanta Hospital and Research InstituteThane, IndiaContact: Ajay Godse (principal investigator)Taking people
  • Rhythm Heart Institute - A Unit of SLPLVadodara, IndiaNo longer taking part

About the trial

What the trial wants to find out

The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2. Study YSA1 will include participants who are unable or unwilling to use Positive Airway Pressure (PAP) therapy and study YSA2 will include participants who are on PAP therapy for at least 3 months at time of screening and plan to continue PAP therapy during the study.

Read full original descriptionShow less

Participants will be assigned to the Intervention-Specific Appendix (ISA) that reflects their current PAP usage. Participation in the study will last about 76 weeks.

The 4 groups in the trial

  • Eloralintide (YSA1)Treatment being tested

    Participants will receive eloralintide subcutaneously (SC)

    Treatment: Eloralintide

  • Placebo (YSA1)Placebo, for comparison

    Participants will receive placebo SC

    Treatment: Placebo

  • Eloralintide (YSA2)Treatment being tested

    Participants will receive eloralintide SC

    Treatment: Eloralintide

  • Placebo (YSA2)Placebo, for comparison

    Participants will receive placebo SC

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Moderate to Severe Obstructive Sleep Apnea, and Obesity or Overweight
Plain-language title
Eloralintide for Obstructive Sleep Apnea in Adults With Obesity or OverweightGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
4 November 2026